Zach Sweeney is the CEO at Interline Therapeutics, an Affiliate at ARCH Venture Partners and a Venture Partner at Foresite Labs. He has broad experience growing and leading successful multifunctional drug discovery groups, including small molecule, biotherapeutic, and AAV discovery platforms.
Zach was previously the Chief Scientific Officer at Denali Therapeutics, where he guided the growth of the discovery portfolio and research group. Prior to joining Denali, Zach was a leader in the drug discovery groups at Revolution Medicines, Novartis, Genentech, and Roche. Molecules that Zach and his teams have developed at these companies have been the subject of several major licensing deals that cumulatively generated more than $1B in upfront payments.
Zach attended Stanford University, where he received a B.S. degree in Chemistry. He subsequently earned a Ph.D. in Chemistry from the University of California, Berkeley, and completed a NIH postdoctoral fellowship at Harvard University. Zach’s research interests include the application of genomic and biomarker information in drug discovery, computational approaches to improve small molecule and biotherapeutic design, and the chemical biology of drug candidates. He is listed as an inventor on approximately 60 published patent applications and has co-authored more than 40 scientific publications.